Options Brief: Cleveland BioLabs (CBLI)

Benzinga's Options & Vol Edge just made over 300% on IBM for its subscribers. See the next pick here before it's too late. Shares of Cleveland BioLabs CBLI are higher on the session by 3.10%, trading at $7.64. Overall call volume is now running at 2.95x the daily average, with 60% of all calls traded being purchases on the offer. 1,323 contracts have traded on the session so far. Cleveland BioLabs, Inc., incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.